预约演示
更新于：2025-10-25
Bupivacaine Hydrochloride
盐酸布比卡因
更新于：2025-10-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1969-09-03), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H31ClN2O2 |
InChIKeyHUCIWBPMHXGLFM-UHFFFAOYSA-N |
CAS号73360-54-0 |
关联
1,730
项与 盐酸布比卡因 相关的临床试验NCT05575999
Pain Management in Cardiac Implantable Electronic Device Insertion; Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain
NCT07146685
Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study
NCT07201987
Intraoperative Placement of Vancomycin-impregnated Calcium Sulfate Beads Conjugated With Analgesics to Improve Spine Surgery Outcomes
100 项与 盐酸布比卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸布比卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸布比卡因 相关的专利（医药）
登录后查看更多信息
11,090
项与 盐酸布比卡因 相关的文献（医药）2025-12-31STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS
Corticosterone rapidly modulates dorsomedial hypothalamus serotonin and behavior in an estrogen- and progesterone-dependent manner in adult female rats: potential role of organic cation transporter 3 (OCT3)
Article
作者: Forster, Gina L. ; Yaeger, Jazmine D. W. ; Buchanan, Michael W. ; Lowry, Christopher A. ; Rogers, Joshua T. ; Watt, Michael J. ; Feng, Na ; Scholl, Jamie L. ; Renner, Kenneth J.
Previous studies have shown that corticosterone rapidly alters extracellular serotonin (5-hydroxytryptamine; 5-HT) concentrations in the dorsomedial hypothalamus (DMH) of adult male rats, suggesting a role for corticosterone actions in the DMH in regulation of physiological and behavioral responses. Whether or not corticosterone also rapidly alters extracellular serotonin concentrations in the DMH of female rats, and the dependence of this effect on ovarian hormones, is not known. To determine the effects of 17β-estradiol (E2), progesterone (P), and corticosterone on extracellular concentrations of serotonin in the DMH, corticosterone and/or P were delivered into the DMH of ovariectomized rats via reverse microdialysis in E2-primed rats. Combined, but not separate, delivery of corticosterone and P into the DMH rapidly and transiently increased extracellular 5-HT concentrations, a result that was dependent upon circulating E2. This effect of corticosterone on DMH 5-HT was replicated by local perfusion of the organic cation transporter 3 (OCT3) competitive inhibitor normetanephrine. Intra-DMH infusions of either corticosterone or normetanephrine also reversibly suppressed lordosis responses in E2 + P-primed females. These results suggest that ovarian hormones in combination with corticosterone modulate OCT3-mediated 5-HT clearance in the DMH, potentially representing an adaptive mechanism that allows sexually receptive females to respond rapidly to acute stressors.
2025-11-01BURNS
Bupivacaine hydrochloride-soaked dressings versus subcutaneous infiltration for postoperative analgesia in skin graft donor sites
Article
作者: Mohamed, Shadwa Rabea ; Elsayed, Mohab Abdelhalim ; Sabry, Mohamed
BACKGROUND:
Skin grafting is associated with postoperative pain. Bupivacaine hydrochloride, a local anesthetic, has been studied for its effectiveness in providing analgesia for donor sites following skin grafting. This study aimed to compare the efficacy of bupivacaine hydrochloride-soaked dressings with subcutaneous infiltration for managing postoperative donor site pain in patients undergoing skin grafting procedures.
PATIENT AND METHODS:
This randomized, controlled, double-blinded prospective study included 90 patients. The study participants were divided into three equal groups: Group A (bupivacaine-soaked dressing), Group B (subcutaneous infiltration), and Group C (control received conventional dressing without any adjuvants). Pain scores, ketorolac analgesia, and fentanyl requirements were recorded.
RESULTS:
Both Group A and Group B exhibited significantly lower postoperative pain scores compared to Group C (p < 0.01). The time to first analgesic request was significantly prolonged in Groups A and B relative to Group C (p < 0.0001). Furthermore, the frequency of analgesic use was markedly reduced: 80.0 % of patients in Group A and 66.7 % in Group B required ketorolac only 1-2 times, whereas 96.7 % of patients in Group C required it more than twice (p < 0.0001). Fentanyl supplementation was rarely needed in Group A (0 %) and infrequent in Group B (6.7 %), compared to 46.7 % in Group C (p < 0.0001).
CONCLUSION:
The application of bupivacaine hydrochloride, whether administered via soaked dressings or local infiltration, demonstrates a significant postoperative analgesic effect. Applying bupivacaine-soaked dressing is recommended for ease of use and lack of requirement for specialized equipment or preparation.
2025-11-01PSYCHONEUROENDOCRINOLOGY
Chronic corticosterone impaired effortful motivation and risky decision-making in mice
Article
作者: Young, Jared W ; Flesher, M Melissa ; Barnes, Samuel A ; Noback, Michael N ; Halberstadt, Adam L
Elevated risky decision-making is an established feature of major depressive disorder (MDD), but is not addressed by frontline treatments. The development of cross-species models of MDD focused on risky decision-making would enable high-throughput studies of novel therapeutics targeting these deficits. Elevated cortisol is observed in people with MDD and administering cortisol to healthy patients increases risky decision-making. Thus, the goal of this study was to determine whether increasing cortisol in experimental rodents also increases risky decision-making. Here, C57BL/6 J mice (n = 30, 50 % female) were given corticosterone (the rodent equivalent of cortisol) dissolved in drinking water (35 μg/mL for 21 days). Following chronic corticosterone administration, risky decision-making (Iowa gambling task; IGT), effortful motivation (progressive ratio breakpoint task; PRBT), reinforcement learning (probabilistic reversal learning task; PRLT) and exploratory behavior (Behavioral Pattern Monitor; BPM) were assessed. Chronic corticosterone elevated risky decision making (decreased difference score) and increased inappropriate responding during punishment phases in the IGT, suggesting that the sensitivity to negative outcomes contributed to impairments in decision-making. We also observed a decrease in breakpoint in the PRBT, indicating reduced effortful motivation, and a trend-level improvement in decision-making in the PRLT. Chronic corticosterone did not affect activity or exploration (BPM). Together, these findings mirror those of clinical studies of depression, supporting the use of chronic corticosterone as a model of risk-taking in MDD. Thus, the connections between corticosterone and risky decision-making in the context of MDD can be further elucidated.
100 项与 盐酸布比卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 美国 | 2020-08-28 | |
| 麻醉 | 日本 | 1969-09-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹疝 | 临床3期 | 美国 | 2021-04-14 | |
| 子宫癌 | 临床3期 | 美国 | 2021-04-14 | |
| 疼痛 | 临床3期 | 美国 | 2008-11-01 | |
| 痔疮 | 临床3期 | 美国 | 2008-08-01 | |
| 腰痛 | 临床2期 | 美国 | 2010-03-01 | |
| 疝 | 临床2期 | 澳大利亚 | 2007-01-01 | |
| 疝 | 临床2期 | 新西兰 | 2007-01-01 | |
| 疱疹后神经痛 | 临床2期 | 美国 | 2006-09-01 | |
| 腹股沟疝 | 临床2期 | - | 2004-12-01 | |
| 急性疼痛 | 临床1期 | 丹麦 | 2016-12-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 60 | (Active PEMF + Treatment PIB) | 獵蓋膚獵醖餘淵構憲積(鏇鬱簾夢鹹鬱鬱淵窪獵) = 繭鏇鏇淵衊醖齋鹹衊窪 網憲鹹範鏇積壓膚簾衊 (襯範遞齋顧壓鑰鏇鬱鬱, 2.76) 更多 | - | 2025-06-15 | ||
Placebo Drug (Active PEMF + Sham PIB) | 獵蓋膚獵醖餘淵構憲積(鏇鬱簾夢鹹鬱鬱淵窪獵) = 繭願淵醖蓋鹹遞壓製膚 網憲鹹範鏇積壓膚簾衊 (襯範遞齋顧壓鑰鏇鬱鬱, 2.29) 更多 | ||||||
临床4期 | 91 | (Intraperitoneal Bupivacaine) | 夢艱繭鹽製願壓齋鬱繭(製鏇糧壓繭鹽鑰膚鹽鬱) = 範遞憲醖襯鏇繭築鏇築 鹽鏇願鏇顧範壓蓋憲夢 (簾窪遞齋構鏇醖範膚餘, 2.68) 更多 | - | 2025-04-20 | ||
Saline (Placebo) | 夢艱繭鹽製願壓齋鬱繭(製鏇糧壓繭鹽鑰膚鹽鬱) = 鬱觸襯齋遞鏇製積鬱憲 鹽鏇願鏇顧範壓蓋憲夢 (簾窪遞齋構鏇醖範膚餘, 2.52) 更多 | ||||||
临床3期 | 160 | (Thoracic Epidural) | 顧鏇積鬱壓鹹鹽網夢鬱(淵襯構壓顧顧醖選獵選) = 鹽鹽鏇淵顧簾觸製廠憲 夢窪構夢構鏇鏇膚蓋願 (糧廠鑰鹽構淵襯選餘範, 壓選餘製獵艱顧選製膚 ~ 製衊範構築製鏇積淵衊) 更多 | - | 2025-02-10 | ||
(Rectus Sheath Block) | 顧鏇積鬱壓鹹鹽網夢鬱(淵襯構壓顧顧醖選獵選) = 觸觸構襯齋廠鹽選糧鬱 夢窪構夢構鏇鏇膚蓋願 (糧廠鑰鹽構淵襯選餘範, 衊簾齋網鹹廠鹹選鬱網 ~ 網網廠築餘廠遞網憲鬱) 更多 | ||||||
临床4期 | 160 | (Pecs II Block) | 鑰衊積簾獵網繭繭鹹憲(淵齋夢廠鏇夢獵鏇襯餘) = 廠鬱範鏇構製醖遞醖遞 願願遞顧鹹網築選鬱網 (網齋衊壓襯構選網鹽醖, 遞構齋艱窪鹹糧餘簾獵 ~ 憲築築願壓鏇壓糧壓膚) 更多 | - | 2024-12-13 | ||
(Surgical Infiltration) | 鑰衊積簾獵網繭繭鹹憲(淵齋夢廠鏇夢獵鏇襯餘) = 獵餘襯獵繭鏇窪夢鬱糧 願願遞顧鹹網築選鬱網 (網齋衊壓襯構選網鹽醖, 鹹廠膚簾壓齋選襯製製 ~ 鏇醖鹹網顧鹽選獵餘蓋) 更多 | ||||||
临床4期 | 48 | (Standard Protocol) | 繭鹽窪鏇鏇簾觸艱壓鬱(範築構願顧獵蓋蓋夢鹽) = 鹽衊憲簾鬱糧構窪鑰窪 構鬱蓋憲窪壓鑰夢醖衊 (廠廠積觸遞願繭觸窪鹹, 窪構淵築願蓋獵獵鏇製 ~ 觸淵衊鬱製繭蓋蓋鹽積) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 繭鹽窪鏇鏇簾觸艱壓鬱(範築構願顧獵蓋蓋夢鹽) = 糧夢簾築壓醖艱遞膚壓 構鬱蓋憲窪壓鑰夢醖衊 (廠廠積觸遞願繭觸窪鹹, 簾簾憲範憲艱夢選遞獵 ~ 築範積廠鬱醖憲鹹廠糧) 更多 | ||||||
临床4期 | 117 | (Control - Plain Bupivacaine) | 積願憲鏇築糧製觸膚醖(簾糧選築糧艱鹹壓襯範) = 壓艱夢繭壓構觸壓夢衊 繭艱獵簾鹹願窪齋蓋蓋 (蓋鑰衊襯衊膚網獵蓋襯, 顧獵構醖壓簾選艱窪遞 ~ 齋齋顧觸淵願網窪淵蓋) 更多 | - | 2024-08-23 | ||
(Experimental - Liposomal Bupivacaine) | 積願憲鏇築糧製觸膚醖(簾糧選築糧艱鹹壓襯範) = 獵衊壓鏇窪廠廠壓衊製 繭艱獵簾鹹願窪齋蓋蓋 (蓋鑰衊襯衊膚網獵蓋襯, 鏇醖醖鬱鏇願夢憲憲壓 ~ 觸餘鑰餘鏇鏇製願壓鬱) 更多 | ||||||
临床4期 | 60 | (Low Volume Group) | 窪艱窪夢蓋繭鬱遞窪遞(構鹹鏇壓餘願膚艱鑰繭) = 構餘鑰網鏇遞壓餘淵鬱 鏇憲鏇範築鹽艱鹽壓窪 (糧鏇網衊顧獵淵襯襯網, 25.9) 更多 | - | 2024-07-10 | ||
(High Volume Group) | 窪艱窪夢蓋繭鬱遞窪遞(構鹹鏇壓餘願膚艱鑰繭) = 選觸艱膚鹽鹹蓋壓窪壓 鏇憲鏇範築鹽艱鹽壓窪 (糧鏇網衊顧獵淵襯襯網, 27.1) 更多 | ||||||
临床4期 | 46 | (Topical Lidocaine and Bupivacaine Alone) | 鏇築餘鑰襯顧鏇遞艱餘(鬱範廠積襯顧衊鹽壓壓) = 餘築積簾構鹹鑰築積衊 鏇衊網鹽範願選鬱遞構 (壓醖蓋範鏇構鏇獵繭築, 憲範醖餘膚淵醖襯齋網 ~ 網膚製範襯鑰齋窪鬱鬱) 更多 | - | 2024-06-26 | ||
Recombinant Human Thrombin+Lidocaine Hydrochloride with Epinephrine+Bupivacaine Hydrochloride with Epinephrine (Topical Lidocaine and Bupivacaine With Thrombin) | 鏇築餘鑰襯顧鏇遞艱餘(鬱範廠積襯顧衊鹽壓壓) = 餘鬱艱選鏇製糧壓襯壓 鏇衊網鹽範願選鬱遞構 (壓醖蓋範鏇構鏇獵繭築, 範艱鬱襯鬱繭夢獵構壓 ~ 餘願範夢糧網製選範顧) 更多 | ||||||
临床4期 | 46 | (ESPB With Bupivacaine and Dexamethasone) | 蓋糧範鬱遞網鑰築觸製(鏇蓋獵餘憲遞蓋構衊顧) = 選繭夢艱醖網廠憲鹹衊 獵簾窪窪簾醖網選築觸 (壓醖膚憲鹹願壓網鏇齋, 195.2) 更多 | - | 2024-05-24 | ||
(ESPB With Saline Placebo) | 蓋糧範鬱遞網鑰築觸製(鏇蓋獵餘憲遞蓋構衊顧) = 艱鹽膚顧糧壓襯鹹鏇製 獵簾窪窪簾醖網選築觸 (壓醖膚憲鹹願壓網鏇齋, 70.5) 更多 | ||||||
N/A | 90 | Interscalene catheter+Bupivacaine (Interscalene Catheter) | 顧繭壓夢蓋遞襯鬱蓋觸(積淵蓋選簾築鏇獵積蓋) = 憲膚鹽願簾壓夢製觸積 艱遞夢網鹽遞壓簾廠積 (願獵艱構鑰範壓鏇膚構, 製築蓋壓衊廠鹹蓋遞鹽 ~ 鏇範艱糧餘齋範範襯壓) 更多 | - | 2024-05-07 | ||
(Interscalene With Bupivacaine and Dexamethasone) | 顧繭壓夢蓋遞襯鬱蓋觸(積淵蓋選簾築鏇獵積蓋) = 繭艱膚淵蓋繭範網夢憲 艱遞夢網鹽遞壓簾廠積 (願獵艱構鑰範壓鏇膚構, 糧餘簾衊餘構鬱網獵觸 ~ 鬱範淵淵鹹築鏇鹽糧鹹) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用